Tirzepatide, an FDA-approved dual GIP/GLP-1 receptor agonist for type 2 diabetes and obesity, works through incretin-based glucose regulation and appetite suppression
As discussed previously, a tentative example of selective effect would be modulation of S1PR2 in astrocytes, which seems to be linked to glutamate recycling and mitochondrial metabolism (116), both promising mechanisms to ameliorate excitotoxic synaptopathy
It affects the GLP one receptor but also the GIP receptor, which are both involved in hunger and satiety and motility. Dan Azagury, MD, FACS, the chief bariatric surgeon and medical director of Stanford University School of Medicines Lifestyle and Weight Management Clinic in California, who also was not involved in the Eli Lilly study, told Healthline that he was not surprised at the studys results
Available online at: (accessed March 14, 2024)
Protein also provides greater satiety per calorie than carbohydrates or fats (which typically have a thermic effect of 5-10% and 0-3%, respectively), which can be beneficial when appetite is already suppressed
